{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:41:12Z","timestamp":1771735272035,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006512","name":"School of Medicine, Duke University","doi-asserted-by":"publisher","award":["2017\/0033"],"award-info":[{"award-number":["2017\/0033"]}],"id":[{"id":"10.13039\/100006512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016017","name":"Duke-NUS Medical School","doi-asserted-by":"crossref","award":["2017\/0033"],"award-info":[{"award-number":["2017\/0033"]}],"id":[{"id":"10.13039\/100016017","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The presence of hereditary cancer syndromes in cancer patients can have an impact on current clinical care and post-treatment prevention and surveillance measures. Several barriers inhibit identification of hereditary cancer syndromes in routine practice. This paper describes the impact of using a patient-facing family health history risk assessment platform on the identification and referral of breast cancer patients to genetic counselling services.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a hybrid implementation-effectiveness study completed in breast cancer clinics. English-literate patients not previously referred for genetic counselling and\/or gone through genetic testing were offered enrollment. Consented participants were provided educational materials on family health history collection, entered their family health history into the platform and completed a satisfaction survey. Upon completion, participants and their clinicians were given personalized risk reports. Chart abstraction was done to identify actions taken by patients, providers and genetic counsellors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 195 patients approached, 102 consented and completed the study (mean age 55.7, 100\u2009% women). Sixty-six (65\u2009%) met guideline criteria for genetic counseling of which 24 (36\u2009%) were referred for genetic counseling. Of those referred, 13 (54\u2009%) participants attended and eight (33\u2009%) completed genetic testing. On multivariate logistic regression, referral was not associated with age, cancer stage, or race but was associated with clinical provider (<jats:italic>p<\/jats:italic>\u2009=\u20090.041). Most providers (71\u2009%) had higher referral rates during the study compared to prior. The majority of participants found the experience useful (84\u2009%), were more aware of their health risks (83\u2009%), and were likely to recommend using a patient-facing platform to others (69\u2009%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>65\u2009% of patients attending breast cancer clinics in this study are at-risk for hereditary conditions based on current guidelines. Using a patient-facing risk assessment platform enhances the ability to identify these patients systematically and with widespread acceptability and recognized value by patients. As only a third of at-risk participants received referrals for genetic counseling, further understanding barriers to referral is needed to optimize hereditary risk assessment in oncology practices.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>NIH Clinical Trials registry, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04639934?term=NCT04639934&amp;draw=2&amp;rank=1\">NCT04639934<\/jats:ext-link>. Registered Nov 23, 2020 -- Retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13053-021-00177-y","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T20:02:41Z","timestamp":1616270561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical implementation of an oncology\u2010specific family health history risk assessment tool"],"prefix":"10.1186","volume":"19","author":[{"given":"Si Ming","family":"Fung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Ryanne","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey S.","family":"Ginsburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Matchar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori A.","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Ngeow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"177_CR1","doi-asserted-by":"crossref","unstructured":"Roos A, Byron SA. Genomics-Enabled Precision Medicine for Cancer. In: Von Hoff D, Han H, editors. Precis Med Cancer Ther Cancer Treat Res. vol\u00a0178. Springer, Cham; 2019. p.\u00a0137\u201369.","DOI":"10.1007\/978-3-030-16391-4_5"},{"key":"177_CR2","doi-asserted-by":"crossref","unstructured":"Tischler J, Crew KD, Chung WK. Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management. Ann Intern Med. 2019;1\u20137.","DOI":"10.7326\/M18-2417"},{"key":"177_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.mrfmmm.2015.03.014","volume":"776","author":"AY Maslov","year":"2015","unstructured":"Maslov AY, Quispe-Tintaya W, Gorbacheva T, White RR, Vijg J. High-throughput sequencing in mutation detection: A new generation of genotoxicity tests? Mutat Res. 2015;776:136\u201343.","journal-title":"Mutat Res"},{"key":"177_CR4","doi-asserted-by":"crossref","unstructured":"Apostolou P, Fostira F. Hereditary breast cancer: The Era of new susceptibility genes. Biomed Res Int. 2013;2013.","DOI":"10.1155\/2013\/747318"},{"key":"177_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","volume":"23","author":"JE Garber","year":"2005","unstructured":"Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23:276\u201392.","journal-title":"J Clin Oncol"},{"key":"177_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/gim.2015.41","volume":"17","author":"ACMG Board of Directors","year":"2015","unstructured":"ACMG Board of Directors. Clinical utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2015;17:505\u20137.","journal-title":"Genet Med"},{"key":"177_CR7","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1245\/s10434-015-4715-9","volume":"22","author":"S Pruthi","year":"2015","unstructured":"Pruthi S, Heisey RE, Bevers TB. Chemoprevention for Breast Cancer. Ann Surg Oncol. 2015;22:3230\u20135.","journal-title":"Ann Surg Oncol"},{"key":"177_CR8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, Evans DG, Henry T, Isaacs C, et al. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality. JAMA. 2010;304:967\u201375.","journal-title":"JAMA"},{"key":"177_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","volume":"119","author":"NM Tung","year":"2018","unstructured":"Tung NM, Garber JE. BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018;119:141\u201352.","journal-title":"Br J Cancer"},{"key":"177_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med United States. 2009;361:123\u201334.","journal-title":"N Engl J Med United States"},{"key":"177_CR11","first-page":"21","volume":"19","author":"D Kamel","year":"2018","unstructured":"Kamel D, Gray C, Walia JS, Kumar V. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. Curr Drug Targets United Arab Emirates. 2018;19:21\u201337.","journal-title":"Curr Drug Targets United Arab Emirates"},{"key":"177_CR12","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","volume":"25","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, Gay CM, Byers LA, O\u2019Connor MJ, Yap TA. PARP inhibitors: Extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25:3759\u201371.","journal-title":"Clin Cancer Res"},{"key":"177_CR13","doi-asserted-by":"crossref","unstructured":"Evans DG, Graham J, O\u2019Connell S, Arnold S, Fitzsimmons D. Familial breast cancer: Summary of updated NICE guidance. BMJ. British Medical Journal Publishing Group; 2013.","DOI":"10.1136\/bmj.f3829"},{"key":"177_CR14","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.6004\/jnccn.2016.0108","volume":"14","author":"D Provenzale","year":"2016","unstructured":"Provenzale D, Gupta S, Ahnen DJ, Bray T, Cannon JA, Cooper G, et al. Genetic\/familial high-risk assessment: Colorectal version 1.2016: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw Harborside Press. 2016;14:1010\u201330.","journal-title":"JNCCN J Natl Compr Cancer Netw Harborside Press"},{"key":"177_CR15","doi-asserted-by":"crossref","unstructured":"Obeng AO, Fei K, Levy KD, Elsey AR, Pollin TI, Ramirez AH, et al. Physician-reported benefits and barriers to clinical implementation of genomic medicine: A multi-site iGNITE-network survey. J Pers Med. 2018;8.","DOI":"10.3390\/jpm8030024"},{"key":"177_CR16","unstructured":"Manolio TA, Rowley R, Williams MS, Roden D, Ginsburg GS, Bult C, et al. Opportunities, resources, and techniques for implementing genomics in clinical care. Lancet. Elsevier Ltd; 2019;6736:1\u201310."},{"key":"177_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/gim.2014.147","volume":"17","author":"H Hampel","year":"2015","unstructured":"Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral indications for cancer predisposition assessment. Genet Med. 2015;17:70\u201387.","journal-title":"Genet Med"},{"key":"177_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3322\/caac.20143","volume":"62","author":"RA Smith","year":"2012","unstructured":"Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2012;62:129\u201342.","journal-title":"CA Cancer J Clin"},{"key":"177_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0140-6736(19)31275-9","volume":"394","author":"GS Ginsburg","year":"2019","unstructured":"Ginsburg GS, Wu RR, Orlando LA. Family health history: underused for actionable risk assessment. Lancet. 2019;394:596\u2013603.","journal-title":"Lancet"},{"key":"177_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000101759","volume":"10","author":"HJ Murff","year":"2007","unstructured":"Murff HJ, Greevy RA, Syngal S. The Comprehensiveness of Family Cancer History Assessments in Primary Care. Public Health Genomics. 2007;10:174\u201380.","journal-title":"Public Health Genomics"},{"key":"177_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejca.2018.02.028","volume":"95","author":"TP McVeigh","year":"2018","unstructured":"McVeigh TP, Sundar R, Diamantis N, Kaye SB, Banerji U, Lopez JS, et al. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. Eur J Cancer. 2018;95:20\u20139.","journal-title":"Eur J Cancer"},{"key":"177_CR22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1200\/JCO.2017.35.15_suppl.1586","volume":"35","author":"JE McGuinness","year":"2017","unstructured":"McGuinness JE, Trivedi MS, Vanegas A, Colbeth H, Sandoval R, Kukafka R, et al. Decision support for family history intake to determine eligibility for BRCA testing among multiethnic women. J Clin Oncol American Society of Clinical Oncology. 2017;35:1586\u20136.","journal-title":"J Clin Oncol American Society of Clinical Oncology"},{"key":"177_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0749-3797(02)00592-5","volume":"24","author":"J Audrain-McGovern","year":"2003","unstructured":"Audrain-McGovern J, Hughes C, Patterson F. Effecting behavior change: awareness of family history. Am J Prev Med Elsevier. 2003;24:183\u20139.","journal-title":"Am J Prev Med Elsevier"},{"key":"177_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/fampra\/16.4.420","volume":"16","author":"EK Watson","year":"1999","unstructured":"Watson EK, Shickle D, Qureshi N, Emery J, Austoker J. The new genetics and primary care: GPs\u2019 views on their role and their educational needs. Fam Pract Narnia. 1999;16:420\u20135.","journal-title":"Fam Pract Narnia"},{"key":"177_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000160667","volume":"12","author":"GT Reid","year":"2009","unstructured":"Reid GT, Walter FM, Brisbane JM, Emery JD. Family History Questionnaires Designed for Clinical Use: A Systematic Review. Public Health Genomics. 2009;12:73\u201383.","journal-title":"Public Health Genomics"},{"key":"177_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/GIM.0b013e3181a7e8e0","volume":"11","author":"N Qureshi","year":"2009","unstructured":"Qureshi N, Carroll JC, Wilson B, Santaguida P, Allanson J, Brouwers M, et al. The current state of cancer family history collection tools in primary care: a systematic review. Genet Med. 2009;11:495\u2013506.","journal-title":"Genet Med"},{"key":"177_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.amepre.2009.03.002","volume":"36","author":"SM O\u2019Neill","year":"2009","unstructured":"O\u2019Neill SM, Rubinstein WS, Wang C, Yoon PW, Acheson LS, Rothrock N, et al. Familial risk for common diseases in primary care: the Family Healthware Impact Trial. Am J Prev Med Netherlands. 2009;36:506\u201314.","journal-title":"Am J Prev Med Netherlands"},{"key":"177_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-15-1","volume":"15","author":"RR Wu","year":"2014","unstructured":"Wu RR, Himmel TL, Buchanan AH, Powell KP, Hauser ER, Ginsburg GS, et al. Quality of family history collection with use of a patient facing family history assessment tool. BMC Fam Pract BMC Family Practice. 2014;15:1\u20138.","journal-title":"BMC Fam Pract BMC Family Practice"},{"key":"177_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.2002.20.2.528","volume":"20","author":"KM Sweet","year":"2002","unstructured":"Sweet KM, Bradley TL, Westman JA. Identification and Referral of Families at High Risk for Cancer Susceptibility. J Clin Oncol American Society of Clinical Oncology (ASCO). 2002;20:528\u201337.","journal-title":"J Clin Oncol American Society of Clinical Oncology (ASCO)"},{"key":"177_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1159\/000294415","volume":"13","author":"WF Cohn","year":"2010","unstructured":"Cohn WF, Ropka ME, Pelletier SL, Barrett JR, Kinzie MB, Harrison MB, et al. Health Heritage\u00a9, a web-based tool for the collection and assessment of family health history: Initial user experience and analytic validity. Public Health Genomics. 2010;13:477\u201391.","journal-title":"Public Health Genomics"},{"key":"177_CR31","first-page":"287","volume":"74","author":"LA Orlando","year":"2013","unstructured":"Orlando LA, Buchanan AH, Hahn SE, Christianson C, Powell K, Skinner CS, et al. Development and Validation of a Primary Care-Based Family Health History and Decision Support Program (MeTree) HHS Public Access. N C Med J. 2013;74:287\u201396.","journal-title":"N C Med J"},{"key":"177_CR32","first-page":"1020","volume":"18","author":"LA Orlando","year":"2016","unstructured":"Orlando LA, Wu RR, Myers RA, Buchanan AH, Henrich VC, Hauser ER, et al. Clinical utility of a Web-enabled risk-assessment and clinical decision support program. Genet Med IOP Publishing. 2016;18:1020\u20138.","journal-title":"Genet Med IOP Publishing"},{"key":"177_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41436-018-0049-x","volume":"21","author":"RR Wu","year":"2019","unstructured":"Wu RR, Myers RA, Sperber N, Voils CI, Neuner J, McCarty CA, et al. Implementation, adoption, and utility of family health history risk assessment in diverse care settings: evaluating implementation processes and impact with an implementation framework. Genet Med Springer US. 2019;21:331\u20138.","journal-title":"Genet Med Springer US"},{"key":"177_CR34","doi-asserted-by":"crossref","unstructured":"Orlando L, Wu R, Myers R, Neuner J, McCarty C, Haller I, et al. At the intersection of precision medicine and population health: An implementation-effectiveness study of family health history based systematic risk assessment in primary care. BMC Health Serv Res. 2020.","DOI":"10.1186\/s12913-020-05868-1"},{"key":"177_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","volume":"50","author":"GM Curran","year":"2012","unstructured":"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50:217\u201326.","journal-title":"Med Care"},{"key":"177_CR36","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/ijc.28875","volume":"135","author":"K Kast","year":"2014","unstructured":"Kast K, Schmutzler RK, Rhiem K, Kiechle M, Fischer C, Niederacher D, et al. Validation of the Manchester scoring system for predicting BRCA1\/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. Int J cancer United States. 2014;135:2352\u201361.","journal-title":"Int J cancer United States"},{"key":"177_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-14-1","volume":"14","author":"RR Wu","year":"2013","unstructured":"Wu RR, Orlando LA, Himmel TL, Buchanan AH, Powell KP, Hauser ER, et al. Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: A type 2 hybrid controlled implementation-effectiveness trial. BMC Fam Pract BMC Family Practice. 2013;14:1.","journal-title":"BMC Fam Pract BMC Family Practice"},{"key":"177_CR38","unstructured":"Wong WK. Population Trends 2018 [Internet]. Dep. Stat. Minist. Trade Ind. Repub. Singapore. 2018. Available from: http:\/\/www.singstat.gov.sg\/."},{"key":"177_CR39","unstructured":"National Registry of Disease Singapore. Trends of Female Breast Cancer in Singapore 2006\u20132010. A Publ Natl Regist Dis Off Singapore Heal Factsheet, July 27, 2012, INP-12-3. 2012;2012:2006\u201310."},{"key":"177_CR40","first-page":"e58","volume":"63","author":"JC Carroll","year":"2017","unstructured":"Carroll JC, Campbell-Scherer D, Permaul JA, Myers J, Manca DP, Meaney C, et al. Assessing family history of chronic disease in primary care: Prevalence, documentation, and appropriate screening. Can Fam Physician. 2017;63:e58\u201367.","journal-title":"Can Fam Physician"},{"key":"177_CR41","doi-asserted-by":"crossref","unstructured":"Rubinstein WS, Acheson LS, O\u2019Neill SM, Ruffin MT 4th, Wang C, Beaumont JL, et al. Clinical utility of family history for cancer screening and referral in primary care: a report from the Family Healthware Impact Trial. Genet Med. 2011;13:956\u201365.","DOI":"10.1097\/GIM.0b013e3182241d88"},{"key":"177_CR42","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/GIM.0b013e3181ab2295","volume":"11","author":"MS Daniels","year":"2009","unstructured":"Daniels MS, Urbauer DL, Stanley JL, Johnson KG, Lu KH. Timing of BRCA1\/BRCA2 genetic testing in women with ovarian cancer. Genet Med. 2009;11:624\u20138.","journal-title":"Genet Med"},{"key":"177_CR43","doi-asserted-by":"crossref","unstructured":"Knabben L, Imboden S, Mueller MD. Genetic testing in ovarian cancer - Clinical impact and current practices. Horm Mol Biol Clin Investig. 2019;1\u20137.","DOI":"10.1515\/hmbci-2019-0025"},{"key":"177_CR44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/ejhg.2014.180","volume":"23","author":"T Delikurt","year":"2015","unstructured":"Delikurt T, Williamson GR, Anastasiadou V, Skirton H. A systematic review of factors that act as barriers to patient referral to genetic services. Eur J Hum Genet. 2015;23:739\u201345.","journal-title":"Eur J Hum Genet"},{"key":"177_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.clon.2013.11.029","volume":"26","author":"SGW Ow","year":"2014","unstructured":"Ow SGW, Yong YFL, Chieng WS, Phyu PS, Lee SC. Inadequate family history assessment by oncologists is an important physician barrier to referral for hereditary breast cancer evaluation. Clin Oncol. 2014;26:174\u20135.","journal-title":"Clin Oncol"},{"key":"177_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jpm4010020","volume":"4","author":"YY Tan","year":"2014","unstructured":"Tan YY, Fitzgerald LJ. Barriers and motivators for referral of patients with suspected lynch syndrome to cancer genetic services: a qualitative study. J Pers Med Switzerland. 2014;4:20\u201334.","journal-title":"J Pers Med Switzerland"},{"key":"177_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cge.12868","volume":"92","author":"AM Willis","year":"2017","unstructured":"Willis AM, Smith SK, Meiser B, Ballinger ML, Thomas DM, Young M-A. Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review. Clin Genet Denmark. 2017;92:121\u201333.","journal-title":"Clin Genet Denmark"},{"key":"177_CR48","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.cdp.2005.06.009","volume":"29","author":"TM Chin","year":"2005","unstructured":"Chin TM, Tan SH, Lim SE, Iau P, Yong WP, Wong SW, et al. Acceptance, motivators, and barriers in attending breast cancer genetic counseling in Asians. Cancer Detect Prev. 2005;29:412\u20138.","journal-title":"Cancer Detect Prev"},{"key":"177_CR49","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/jmedgenet-2016-104302","volume":"54","author":"ST Li","year":"2017","unstructured":"Li ST, Yuen J, Zhou K, Ishak NDB, Chen Y, Met-Domestici M, et al. Impact of subsidies on cancer genetic testing uptake in Singapore. J Med Genet. 2017;54:254\u20139.","journal-title":"J Med Genet"},{"key":"177_CR50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12687-018-0399-8","volume":"10","author":"E Qian","year":"2019","unstructured":"Qian E, Thong MK, Flodman P, Gargus J. A comparative study of patients\u2019 perceptions of genetic and genomic medicine services in California and Malaysia. J Community Genet Journal of Community Genetics. 2019;10:351\u201361.","journal-title":"J Community Genet Journal of Community Genetics"},{"key":"177_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ajmg.1500","volume":"103","author":"MJ Green","year":"2001","unstructured":"Green MJ, Biesecker BB, McInerney AM, Mauger D, Fost N. An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility. Am J Med Genet. 2001;103:16\u201323.","journal-title":"Am J Med Genet"},{"key":"177_CR52","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/1097-0142(20010815)92:4<932::AID-CNCR1403>3.0.CO;2-Q","volume":"92","author":"MD Schwartz","year":"2001","unstructured":"Schwartz MD, Benkendorf J, Lerman C, Isaacs C, Ryan-Robertson A, Johnson L. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1\/BRCA2: Testing among Ashkenazi Jewish women. Cancer. 2001;92:932\u201340.","journal-title":"Cancer"},{"key":"177_CR53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ajmg.a.30577","volume":"134 A","author":"C Wang","year":"2005","unstructured":"Wang C, Gonzalez R, Milliron KJ, Strecher VJ, Merajver SD. Genetic counseling for BRCA1\/2: A randomized controlled trial of two strategies to facilitate the education and counseling process. Am J Med Genet. 2005;134 A:66\u201373.","journal-title":"Am J Med Genet"},{"key":"177_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/07366290500265335","volume":"10","author":"SM Miller","year":"2005","unstructured":"Miller SM, Fleisher L, Roussi P, Buzaglo JS, Schnoll R, Slater E, et al. Facilitating informed decision making about breast cancer risk and genetic counseling among women calling the NCI\u2019s Cancer Information Service. J Health Commun. 2005;10:119\u201336.","journal-title":"J Health Commun"},{"key":"177_CR55","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/pon.1353","volume":"17","author":"CE Wakefield","year":"2008","unstructured":"Wakefield CE, Meiser B, Homewood J, Taylor A, Gleeson M, Williams R, et al. A randomized trial of a breast\/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Psychooncology. 2008;17:844\u201354.","journal-title":"Psychooncology"},{"key":"177_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10689-011-9479-1","volume":"11","author":"A Albada","year":"2012","unstructured":"Albada A, Van Dulmen S, Lindhout D, Bensing JM, Ausems MGEM. A pre-visit tailored website enhances counselees\u2019 realistic expectations and knowledge and fulfils information needs for breast cancer genetic counselling. Fam Cancer. 2012;11:85\u201395.","journal-title":"Fam Cancer"},{"key":"177_CR57","unstructured":"NCCN. Genetic \/ Familial High-Risk Assessment: Breast and Ovarian [Internet]. 2019 [cited 2020 Jan 31]. Available from: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-021-00177-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-021-00177-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-021-00177-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:52:19Z","timestamp":1675054339000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-021-00177-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1186\/s13053-021-00177-y","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Duke University IRB (Pro 00087654) and SingHealth-Centralized Institutional Review Board (CIRB 2018\/2046). Written informed consent was obtained from the participants at recruitment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RW, LO, and GG report a potential conflict of interest as they are co-founders of a company, MeTree&You that in the future will provide MeTree as a clinical service. MeTree&You has not and will not receive any direct financial gain from this study or publication. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}